Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
137.32
-0.26 (-0.19%)
At close: Oct 7, 2025, 4:00 PM EDT
135.90
-1.42 (-1.03%)
After-hours: Oct 7, 2025, 5:07 PM EDT
Jazz Pharmaceuticals Revenue
Jazz Pharmaceuticals had revenue of $1.05B in the quarter ending June 30, 2025, with 2.14% growth. This brings the company's revenue in the last twelve months to $4.09B, up 4.52% year-over-year. In the year 2024, Jazz Pharmaceuticals had annual revenue of $4.07B with 6.12% growth.
Revenue (ttm)
$4.09B
Revenue Growth
+4.52%
P/S Ratio
2.05
Revenue / Employee
$1,459,534
Employees
2,800
Market Cap
8.33B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.07B | 234.75M | 6.12% |
| Dec 31, 2023 | 3.83B | 174.83M | 4.78% |
| Dec 31, 2022 | 3.66B | 565.14M | 18.26% |
| Dec 31, 2021 | 3.09B | 730.67M | 30.91% |
| Dec 31, 2020 | 2.36B | 201.81M | 9.34% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
JAZZ News
- 5 days ago - FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer - PRNewsWire
- 5 days ago - US FDA approves Jazz Pharma's therapy for lung cancer - Reuters
- 13 days ago - Jazz Pharmaceuticals Announces Promising Xywav Data: Why I Assign A BUY Rating - Seeking Alpha
- 15 days ago - Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses - PRNewsWire
- 4 weeks ago - Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma - PRNewsWire
- 4 weeks ago - Jazz Pharmaceuticals Plc (JAZZ) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript - Seeking Alpha
- 6 weeks ago - Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference - PRNewsWire
- 6 weeks ago - Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025 - PRNewsWire